Mario Ezquerra Trabalon, PhD
Area of Focus
- alpha-synuclein
- Biomarker
- Early-Onset PD
- DNA Methylation
- Genetics of Parkinson’s
- LRRK2
- RAB
Biography
Mario Ezquerra is a biologist who has been involved in research of neurodegenerative diseases for 26 years. In the last 15 years, he focused on the investigation of PD and premotor PD. Ongoing research lines as a PI include the research for potential direct LRRK2 targets and downstream phosphorylation cascades (Mov Dis 2022, PMID: 35049090) in PD and in individuals at PD risk (LRRK2 mutation carriers). He is expanding these preliminary findings by using a more powerful phosphoproteome tool (SWATH-MS) with higher quantitative accuracy and consistency, in two different samples, PBMCs (recently finished MJ Fox Foundation, Grant code MJFF-000858, 2022-2024) and cultured fibroblast (ongoing FIS Grant code PI20/00259, PI, 2021-2023). In addition, he will test the phosphoproteomic effect of type II LRRK2 drug inhibitors from Lilly (“DYG-loop in” inhibitor, Lilly Madrid) using a preclinical trial using cultured fibroblast and PBMCs as PD cell model. Currently, he is committed to following research lines focused on using omics techniques in personalized medicine to improve clinical practice and with potentially great implications for public health.